Viracta Therapeutics, Inc. / Fundamentals

    Income statement

    Net revenue
    €633.20K
    Cost of goods sold
    €282.28K
    Gross profit
    €350.92K
    SG&A expenses
    €11.91M
    R&D expenses
    €28.39M
    EBITDA
    -€34.03M
    D&A
    €376.66K
    EBIT
    -€40.51M
    Interest expenses
    €2.73M
    EBT
    -€37.14M
    Tax expenses
    -€409.50K
    Net income
    -€37.14M

    Cash flow statement

    Net deferred tax
    -€1.67M
    Non-cash items
    €3.62M
    Changes in working capital
    €1.98M
    Operating cash flow
    -€29.85M
    Capex
    €0.00
    Other investing cash flow
    €12.18M
    Net investing cash flow
    €37.17M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €216.22K
    Debt repayment
    -€7.38M
    Other financing cash flow
    €77.22K
    Net financing cash flow
    -€7.09M
    Foreign exchange effects
    €0.00
    Net change in cash
    €232.52K
    Cash at end of period
    €11.26M
    Free cash flow
    -€29.85M

    Balance sheet

    Cash and cash equivalents
    €11.26M
    Cash and short-term investments
    €18.13M
    Total receivables
    €0.00
    Inventory
    €0.00
    Other current assets
    €575.72K
    Total current assets
    €18.71M
    Property, plant & equipment
    €95.24K
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €37.75K
    Total non-current assets
    €132.99K
    Total assets
    €18.84M
    Accounts payable
    €1.56M
    Short-term debt
    €14.51M
    Other current liabilities
    €8.45M
    Total current liabilities
    €24.52M
    Long-term debt
    €0.00
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €0.00
    Total non-current liabilities
    €0.00
    Total liabilities
    €24.52M
    Common stock
    €3.43K
    Retained earnings
    -€253.50M
    Other equity
    €7.72K
    Total equity
    -€5.68M
    Total liabilities and shareholders' equity
    €18.84M

    Company information

    Market capitalization
    €603.42K
    Employees
    26
    Enterprise Value
    €4.54M

    Company ratios

    Gross margin
    55.4% Much better than peer group: -196,101.1%
    EBITDA margin
    -5,374.9% Much better than peer group: -44,948,631.1%
    EBIT margin
    -6,397.0% Much better than peer group: -44,530,863.8%
    EBT margin
    -5,865.7% Much better than peer group: -45,130,358.7%
    Net margin
    -5,865.7% Much better than peer group: -45,265,915.1%
    ROE
    654.2% Much better than peer group: -136.6%
    ROA
    -197.1% Much worse than peer group: -52.5%
    Asset turnover
    3.4% Even with peer group: 5.8%
    FCF margin
    -4,714.9% Much better than peer group: -38,597,973.7%
    FCF yield
    -4,947.6%
    Efficiency ratio
    5,474.9%
    Net sales per employee
    €24.35K
    Net income per employee
    -€1.43M

    Notifications